triptorelin extended release (FP-014) / Foresee Pharma - LARVOL DELTA

Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Foresee Pharmaceuticals Co., Ltd. | N=148 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Foresee Pharmaceuticals Co., Ltd. | N=148 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Global, phase 3, open-label, single arm studies to evaluate the efficacy, safety, and pharmacokinetics of FP‑014, 11.25 mg (triptorelin mesylate injection, 11.25 mg) and FP-014, 22.5 mg (triptorelin mesylate injection, 22.5 mg) in patients with advanced prostate cancer. (ASCO-GU 2025) - "Two Phase 3 studies are designed to evaluate the safety, efficacy, and pharmacokinetics of long-acting injectable FP-014 (triptorelin mesylate), aiming to demonstrate an alternative therapeutic option for patients with prostate cancer."

Clinical • Metastases • P3 data • PK/PD data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Foresee Pharmaceuticals Announces Acceptance of An Abstract for Presentation at ASCO Genitourinary Cancers Symposium 2025 (PRNewswire) - "The abstract is titled: 'Global, Phase 3, Open-Label, Single-Arm Studies to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg (Triptorelin Mesylate Injection, 11.25 mg) and FP-014, 22.5 mg (Triptorelin Mesylate Injection, 22.5 mg) in Patients with Advanced Prostate Cancer (KATANA studies)...Building on the success of CAMCEVI and our SIF-LAI technology, the KATANA studies will help evaluate the efficacy and safety of FP-014 11.25 mg every 3 months and 22.5 mg, every 6-months injections which have the potential to provide significant benefits for patients with advanced prostate cancer,"

P3 data • Prostate Cancer

Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 Mg in Patients with Advanced Prostate Cancer (clinicaltrials.gov) - P3 | N=148 | Not yet recruiting | Sponsor: Foresee Pharmaceuticals Co., Ltd.

New P3 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 Mg in Patients with Advanced Prostate Cancer (clinicaltrials.gov) - P3 | N=148 | Not yet recruiting | Sponsor: Foresee Pharmaceuticals Co., Ltd.

New P3 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Foresee Pharmaceuticals Announces Completion of US$42.1 Million Financing (PRNewswire) - "Foresee Pharmaceuticals...announces that it has successfully completed an underwritten public offering of 18,000,000 shares of its common stock to the public at a price of NT$76 per share. The aggregate gross proceeds to Foresee from the offering were NT$1,368 million (or US$42.1 million at FX=32.5). The proceeds of the public offering will be used for general corporate purposes, including FP-014 (triptorelin), a ready-to-use long-acting injectable, administered either every three months or six months, in two Phase 3 clinical trials for advanced prostate cancer..."

Financing • Prostate Cancer